Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPI-472372
- Development stage
- Unknown
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
01
Overview
BPI-472372: sourced facts only. name: "Here we present BPI-472372, a potent, selective, and orally bioavailable small molecule CD73 inhibitor." [DOI:10.1158/1538-7445.am2023-504]; target: "Here we present BPI-472372, a potent, selective, and orally bioavailable small molecule CD73 inhibitor." [DOI:10.1158/1538-7445.am2023-504]; developer: "1Betta Pharmaceuticals Co.,Ltd, Hangzhou, China." [DOI:10.1158/1538-7445.am2023-504]; modality: "Here we present BPI-472372, a potent, selective, and orally bioavailable small molecule CD73 inhibitor." [DOI:10.1158/1538-7445.am2023-504]; stage: "In vivo, BPI-472372 exhibited anti-tumor effect in MC38 syngeneic mouse model with no visible adverse effect." [DOI:10.1158/1538-7445.am2023-504]
02
Targets
NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on BPI-472372.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPI-472372.